Kornimate/medical-research-clean huggingface dataset:
reconstruction with a lawrence-hunt jejunal pouch after total gastrectomy

Conditions: Total Gastrectomy; Gastric Cancer

Summary: the aim of the study is to establish the efficacy of jejunal pouch reconstruction in reducing dumping syndrome in patients undergoing total gastrectomy, ultimately enhancing postoperative quality of life and nutritional status.

total gastrectomy (tg) with roux-en-y (ry) esophageal-jejunal anastomosis is performed for various gastric malignancies or as a prophylactic strategy in patients with hereditary diffuse gastric cancer syndrome harboring cdh1 mutation at risk of developing gastric cancer. the surgical procedure is, however, complicated in the post-operative months by weight loss and nutritional deficiency in most patients, requiring frequent follow-up, and by functional issues such as reflux and dumping syndrome in about 30% of cases, which significantly impact the patient's quality of life. to prevent the poorer outcomes reported by patients undergoing total gastrectomy, one strategy could be a modification of the reconstruction method using a jejunal pouch reconstruction (jp) that may mitigate symptoms by slowing gastric emptying and enhancing nutrient absorption. jp has so far proven several benefits in improving postoperative outcomes (reflux and dumping syndrome), nutritional outcomes, and qol up to 2 years after surgery. the technique has been mostly studied in the eastern countries (japan and south korea) and, since 2021, has been recommended by the french association of surgery as the technique of choice for reconstruction after total gastrectomy. however, in most european centers, this technique has not yet been introduced as a routine procedure due to a relative lack of data on the clinical benefit and risk profile in the western population.

Eligibility criteria:
inclusion criteria: * adults aged 18-75 years. * histologically confirmed gastric tumor (including adenocarcinoma, gastrointestinal stromal tumor - gist- or neuroendocrine tumor) or patients with cdh1 mutation, scheduled for tg with a maximal esophageal resection of \< 6 cm. * informed consent capability. exclusion criteria: * prior abdominal surgeries affecting the jejunum. * severe comorbidities or non-appropriate organ function: uncontrolled diabetes with hba1c \> 7.5, significant heart disease: new york heart association (nyha) functional classification class iii or iv, chronic obstructive pulmonary disease (copd) requiring oxygen supplementation or continuous positive airway pressure (cpap), chronic corticosteroid therapy (daily for more than 6 months), neutrophil count \ 1.5 mg/dl, serum aspartate aminotransferase (ast) \>100 iu/l, serum alanine aminotransferase (alt) \>100 iu/l, and creatinine clearance (ccr) ≥ 50 ml/min), ecog performance status \> 1. * pregnancy or breastfeeding.

Keywords: gastric cancer total gastrectomy
evaluating the pharmacokinetic characteristics of ad-102 in healthy volunteers

Conditions: Osteoporosis

Summary: the purpose of this study is to evaluate the pharmacokinetic characteristics of ad-102 in healthy male subjects

this study is to evaluate the pharmacokinetic characteristics and safety of ad-102 compared with administration of raloxifen 60 mg + cholecalciferol 800iu in healthy male subjects

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 17.5 kg/m2 and 30.5 kg/m2 at the time of screening visit * the age between 19 and 50 in healthy male volunteers at the time of screening visit exclusion criteria: * as a result of laboratory tests, the following figures: alt or ast\> 2 times upper limit of normal range * as a result of laboratory tests, the following figures: 25-oh vitamin d total \<9 ng/ml
a retrospective multicenter review to evaluate the performance of the ion endoluminal system in sampling pulmonary lesions

Conditions: Lung Cancer; Pulmonary Nodule

Summary: this study is a retrospective multi-center chart review of patients who underwent an attempted biopsy of one or more pulmonary lesion(s) with the ion endoluminal system with the aim of assessing the overall performance of the system.

this study is a retrospective multi-center chart review of patients who underwent an attempted biopsy of one or more pulmonary lesion(s) with the ion endoluminal system with the aim of assessing the overall performance of the system. the primary objectives of the study will be performance (evaluated by diagnostic yield and sensitivity for malignancy) and safety (assessed by rate of pneumothoraces and bleeding events).

Eligibility criteria:
inclusion criteria: * subject was 18 years or older at the time of the procedure * biopsy procedure attempted/performed using the ion endoluminal system exclusion criteria: * biopsy procedure was not attempted with the ion endoluminal system * biopsy procedure attempted with the ion endoluminal system occurred less than 12 months prior to irb approval
adding insulin to ivf culture media significantly improve outcome

Conditions: Infertility

Summary: add insulin to a single step culture media for ivf embryo culture from day 0 to day 5/6 of in vitro culture and detect the the effect upon embryo quality and implantation potential.

the ivf culture media design and upgrade underwent many ideas during the last 3 decades, we suppose that adding insulin as a hormon and growth factor might improve embryo development in vitro so we decide to design a trial to compare the embryogenesis by sibling oocytes of the same patient between to arm of the same culture media and yhe same culture condition but with one arm with insulin and the other is traditional one and closely monitor the outcome within the 2 arms abd record the results

Eligibility criteria:
inclusion criteria: * normal responder * pcos * tubal factor infertility * mild asthenozoospermia exclusion criteria: * patient over 40

Keywords: in vitro embryo quality intracytoplasmic sperm injection
effects of eccentric training for shoulder abductors in subjects with shoulder impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: the aim of the study was to evaluate the effect of eccentric strength training for shoulder abductors on force steadiness in subjects with subacromial impingement syndrome (sis).

although it is known that shoulder abduction in subjects with subacromial impingement syndrome (sis) presents alterations in several parameters, as for example, in scapular and glenohumeral kinematics, the strengthening of the shoulder abductors as an intervention strategy is controversial in literature. strength training has been shown to be effective in reducing the fluctuations in force and had a positive effect on isometric steadiness in old adults and in healthy young subjects during bed rest. however, there are no studies that evaluated the effects of strength training on the force steadiness in subjects with sis.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with subacromial impingement syndrome by a physical therapist (the diagnosis was confirmed by an orthopaedic physician). exclusion criteria: * pregnancy * torn rotator cuff or long head biceps tendons * ligamentous laxity based on positive sulcus test or a positive apprehension test * previous shoulder or neck surgery * hooked acromion * systemic illnesses * corticosteroid injection 3 months prior to evaluation * physical therapy 6 months prior to evaluation

Keywords: subacromial impingement syndrome muscle strength resistance training
a study of md-120 in patients with depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of md-120 in japanese patients with depression.


Eligibility criteria:
inclusion criteria: * patient with diagnosis of major depressive disorder (mdd) based on the criteria in the diagnostic and statistical manual of mental disorders 5th edition (dsm-5). * hamilton depression rating scale-17 (ham-d17) total score of ≥20. exclusion criteria: * patient who meets dsm-5 criteria of the following disorders for current or past history. schizophrenia spectrum and other psychotic disorders bipolar and related disorders substance use disorders (exclusive of tobacco and caffeine) * patient who had suicidal behavior in columbia-suicide severity rating scale (c-ssrs) within 1 year before start of screening phase.
compliance to synagis (palivizumab) under daily pediatrician´s conditions in premature infants 33 - 35 wga

Conditions: Premature Infants

Summary: compliance to synagis (palivizumab) is a key factor to obtain maximal protection against respiratory syncytial virus (rsv) infection as shown in the impact study. many factors such as parents' knowledge of burden of respiratory syncytial virus disease or physicians' satisfaction with synagis as well as the appropriate use of the product might influence compliance. the primary objective of this observational study is to evaluate the compliance to synagis under daily pediatricians practice conditions in premature infants 33 to 35 weeks gestational age (wga). palivizumab, monoclonal antibody for passive immunoprophylaxis against severe respiratory syncytial virus disease, was administered according to usual clinical practice. compliance was assessed using four criteria: the number of injections per participant per respiratory syncytial virus season, the body site where injections were administered, the interval in days between injections, and the dosage per administration. originally the study was to include two respiratory syncytial virus seasons but was extended to a third season.


Eligibility criteria:
inclusion criteria: * premature infant 33 to 35 weeks gestational age * younger than 3 months at respiratory syncytial virus season start * at least 4 points according to the austrian risk score according to austrian guidelines: 1 point younger than 3 months (at start of respiratory syncytial virus season), 1 point neurologic disease, 1 point weight less than 10th percentile, 1 point discharge from hospital during respiratory syncytial virus season (1 oct - 30 march), 1 point older siblings, 0.5 points multiple births, 0.5 points day care attendance, 0.5 points passive tobacco smoke exposure, 0.5 points socio-economic status (overcrowding) * synagis application (prescription) * signed authorization form for data use (parental authorization) exclusion criteria: * patients without synagis prescription * patients who meet contraindications as outlined in the latest version of synagis summary of product characteristics (smpc): * patients with known hypersensitivity to palivizumab or any component of the formulation or other humanized monoclonal antibodies * patients with chronic lung disease * patients with congenital heart disease * greater than 36 weeks gestational age

Keywords: premature infants respiratory syncytial virus (rsv) compliance palivizumab
phase i pilot study of gene therapy for cystic fibrosis using cationic liposome mediated gene transfer

Conditions: Cystic Fibrosis

Summary: objectives: determine whether copies of the cystic fibrosis gene (pgt-1) can be delivered to the cells lining the nose of cystic fibrosis patients using cationic liposome (dmrie/dope) mediated gene transfer.

protocol outline: under direct visualization, patients receive lipid/dna formulation (pgt-1 lipid complex) by syringe instillation over 30 minutes to the right inferior nasal turbinate. patients are followed daily for 7 days, twice a week for 3 weeks, every 2-3 weeks for 10 weeks, then every 3 months thereafter.

Eligibility criteria:
* cystic fibrosis patients * not pregnant fertile patients must use effective contraception

Keywords: cardiovascular and respiratory diseases cystic fibrosis genetic diseases and dysmorphic syndromes rare disease
emg control assistance virtual reality interface coupled with cerebellar-itbs for arm recovery after stroke (erica)

Conditions: Stroke; Stroke, Cardiovascular

Summary: the investigators hypothesize that a myoelectric (emg) controlled vr interface allows for effective upper limb motor recovery of stroke patients. emg control offers the possibility to alter visual feedback according to the recorded muscle activity in real-time. by manipulating the motion of a virtual hand associated with the recorded muscle patterns, assistance can be provided to stroke patients by correcting the error between the actual (dysfunctional) and a reference (functional) muscle pattern. thus, through such an assistive emg control algorithm, patients will be able to perform reaching movements with the virtual hand despite their motor impairment. by gradually reducing assistance, it is hypothesized that the salient error in the task space provided as visual feedback will systematically change the muscle patterns, thereby driving adaptation of the dysfunctional muscle patterns, enhancing motor recovery. moreover, due to its relevant role in motor learning, it is expected that cerebellar stimulation will favor the underlying processes of adapting cerebello-cortical plasticity involved in motor learning. therefore, it is hypothesized that an assistive emg control algorithm in combination with cerebellar transcranial magnetic stimulation will further enhance upper limb recovery.

theta burst stimulation (tbs) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (ltp) or long-term depression. theta burst stimulation (tbs) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (ltp) or long-term depression (ltd) in animal models. whereas continuous tbs induces long-lasting inhibition of cortical areas, itbs exerts the opposite effect, increasing cerebellar excitability.

Eligibility criteria:
inclusion criteria: * first ever ischemic stroke with mild to moderate motor impairment of upper limb; * left or right sub-cortical or cortical lesion of the middle cerebral artery; * age\>18, \<80 years; * no visuospatial, cognitive, or attention deficits; * fugl-meyer score\<56. exclusion criteria: * history of seizures; * treatment with benzodiazepines, baclofen; * pregnancy status; * intracranial metal implant; * cardiac pace-maker; * orthopedic upper limb limitation; * upper limb pain; * patients with neurological diseases beyond stroke or with neuropsychiatric disorders or with neuropsychological disorders that could potentially compromise informed consent or compliance during the study.

Keywords: virtual reality brain stimulation myoelectric control transcranial magnetic stimulation cerebellar stimulation motor recovery tailored assistance
comparison of sleep study results after partial intracapsular tonsillectomy versus total tonsillectomy

Conditions: Sleep-disordered Breathing; Obstructive Sleep Apnea

Summary: the purpose of this study is to demonstrate similar improvements in sleep-disordered breathing as determined by sleep study with microdebrider-assisted partial intracapsular tonsillectomy and adenoidectomy versus total bovie electrocautery tonsillectomy and adenoidectomy.

objectives: to demonstrate similar improvement in sleep-disordered breathing as determined by polysomnography (psg) with microdebrider-assisted partial intracapsular tonsillectomy and adenoidectomy (pita) versus bovie electrocautery complete tonsillectomy and adenoidectomy (t\&a). methods: in a retrospective cohort study children found to have obstructive sleep apnea (osa) by psg who have undergone either pita or t\&a as treatment will be evaluated with repeat psg. the groups will be matched by age, sex, and severity of pre-operative apnea-hypopnea indices (ahi). the investigators performing and evaluating the psg will be blinded to type of procedure and preoperative ahi. change scores will be computed for each participant and the change scores of the groups compared.

Eligibility criteria:
inclusion criteria: * the medical records of 149 children who underwent partial intracapsular tonsillectomy and adenoidectomy at the state university of new york (suny) downstate medical center or the long island college hospital will be reviewed to identify children with positive preoperative polysomnography. 18 of those with positive preoperative studies will be randomly selected and offered participation in the study. * once enrolled, the participants will be matched by age, sex, time since procedure and polysomnography results (apnea hypopnea index index within 5) to 18 children who underwent traditional tonsillectomy and adenoidectomy (out of a total of 455 patients). exclusion criteria: * recurrent tonsillitis * craniofacial syndromes * neuromuscular disorders * sickle cell disease

Keywords: sleep-disordered breathing obstructive sleep apnea polysomnography tonsillectomy microdebrider assisted partial intracapsular tonsillectomy
investigation of the acute effect of novel olive oil on postprandial oxidative stress biomarkers (biolivect)

Conditions: Cardiometabolic Risk

Summary: the purpose of this study was the investigation of the hypothesis that the enhancement of a refined olive oil with orange peel extract, may improve the postprandial lipidemic, glycemic profile and blood oxidative status, of volunteers with high cardiometabolic risk, due to increased content of bioactive compounds (polyphenols, carotenoids etc.).

in a randomized, acute, single-blinded and cross-over study, participated 21 volunteers with high cardiometabolic risk, aged 30-65, were randomized and divided into two groups. the first group consumed a meal of mashed potatoes with added refined olive oil, rich in fat and carbohydrates (300g, control meal), while the second group consumed mashed potatoes with added olive oil, enhanced with 10% w/w orange peel extract (functional meal). after a one-week washout period, the volunteers were crossed over and consumed the meals in reverse. blood samples were withdrawn in a fasting state, 30, 90 and 180 min after meal consumption. plasma total antioxidant capacity (frap), serum lipid levels \[total, high-density lipoprotein (hdl-) and low-density lipoprotein (ldl-) cholesterol and triglycerides\], glucose and uric acid were determined at each time point using a biochemical analyzer (roche cobas c111).

Eligibility criteria:
inclusion criteria: * age from 30 to 65 years * completion of at least 3 of the following parameters: * hypertension (systolic pressure ≥ 140mm hydrargyrum or diastolic pressure ≥ 90mm hydrargyrum or taking antihypertensive treatment) * high levels of ldl-cholesterol (≥130mg/dl) * high serum triglycerides (≥150mg/dl) * waist circumference \>102cm for men and \>98cm for women * family history (myocardial infarction or sudden death in a 1st degree relative \<55 years old) * high fasting glucose (100-125 mg/dl) exclusion criteria: * diabetes or antidiabetic treatment * age \ 65 years * malignancies * liver disease

Keywords: novel olive oil orange peel extract postprandial bioactivity cardiometabolic risk
study of chitosan for pharmacologic manipulation of age levels in prostate cancer patients

Conditions: Prostate Cancer

Summary: this study will examine the utility of chitosan for reduction of blood or tissue levels of ages in patients with prostate cancer who are clinically stable on androgen-deprivation therapy.

the overall goal of this study is to identify a safe dose of the metabolic supplement, chitosan that can help reduce age (advanced glycation endproducts) levels in patients with prostate cancer. chitosan is a naturally occurring substance found in shellfish. this study will be using chitosan prepared from the shells of cold-water shrimp. chitosan is approved by the fda for use in wound dressings and has been used in published clinical trials for weight loss but is not approved for the purposes of this study. ages are a type of metabolite, or substance, found in food and produced in the body. the researchers helping conduct this study have found a potential link between age levels and cancer. participation in this study will require three study visits over the course of about 3 months. during these visits subjects will be asked to provide blood and stool samples as well as complete surveys about their quality of life.

Eligibility criteria:
inclusion: 1. confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer. 2. subjects must be receiving adt with a gnrh agonist or antagonist, with or without an anti-androgen or testosterone synthesis inhibitor. the current testosterone level must be documented to be \<50ng/dl at enrollment. subjects whose adt is interrupted may enroll or continue on study as long as the testosterone is documented to remain \<50ng/dl for the entire duration of study participation. subjects who have undergone orchiectomy are also eligible. 3. subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows: * hematology parameters: anc \>1000/mcl, platelets \> 100,000/mcl, hgb \>8.0gm/dl * renal function: egfr of ≥ 45mls/min using cockgroft and gault formula * liver function: total bilirubin ≤uln, ast and alt \<1.5x uln 4. able to swallow and retain oral medication 5. ecog performance status of 0 - 2 6. ability to sign written informed consent 7. testosterone level \<50ng/dl at time of enrollment. 8. age 18 or older. 9. may have had prior radiation therapy, surgery, or cryoablation for primary prostate cancer 10. may have had prior cytotoxic chemotherapy for metastatic prostate cancer, prior treatment with genomically-targeted agents, or provenge exclusion: 1. known allergy to chitosan or shellfish. 2. history of receiving more than 2 classes of adt. 3. chronic constipation (bm \< 3x weekly), history of malabsorption or history of daily laxative use. 4. patients requiring medication administration with lunch or dinner or at a frequency of three or more times per day are not eligible. 5. current use of chitosan, sevelamer, and/or glucosamine.